Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus

Hata, Atsuko; Inoue, Fukue; Yamasaki, Midori; Fujikawa, Jun; Kawasaki, Yukiko; Hamamoto, Yoshiyuki; Honjo, Sachiko; Moriishi, Eiko; Mori, Yasuko; Koshiyama, Hiroyuki

doi:10.1016/j.jinf.2013.04.010

Cited by 15 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two points in Hata et al . differed from those in the current study. First, most participants in the current study used dipeptidyl peptidase–4 (DPP–4) inhibitors as anti‐diabetic drugs, whereas participants in Hata et al .…”

Section: Discussioncontrasting

confidence: 99%

“…Missing data for post-vaccination time points are due to protocol deviations and thus results were excluded from the per protocol analyses. Two points in Hata et al [15] differed from those in the current study. First, most participants in the current study used dipeptidyl peptidase-4 (DPP-4) inhibitors as anti-diabetic drugs, whereas participants in Hata et al [15] used only conventional anti-diabetic drugs.…”

Section: Discussioncontrasting

confidence: 91%

“…The varicella zoster vaccine, containing an estimated 50 000 plaque‐forming units per dose derived from the same Oka strain, was expected to be equivalent to the zoster vaccine Zostavax, containing mean titre of 19 000 plaque‐forming units per dose, for the prevention of HZ. An earlier study demonstrated that the same varicella zoster vaccine boosted VZV‐specific, cell‐mediated immunity and humoral immunity in elderly people with or without diabetes . This study found no significant differences in the cell‐mediated immunity responses or in immunogenicity against VZV between the varicella zoster vaccine group and the placebo group under concurrent administration of PPSV23.…”

Section: Discussionmentioning

confidence: 56%

“…First, most participants in the current study used dipeptidyl peptidase–4 (DPP–4) inhibitors as anti‐diabetic drugs, whereas participants in Hata et al . used only conventional anti‐diabetic drugs. Actually, DPP–4 is known as lymphocyte cell‐surface protein CD26.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double‐blind, placebo‐controlled trial

et al. 2015

View full text Add to dashboard Cite

Our previous results demonstrated that varicella zoster vaccine safely enhanced VZV-specific immunity in elderly people with or without diabetes. The results of this study showed that varicella zoster vaccine can be used safely, but it cannot boost virus-specific immunity in elderly people with diabetes when administered with concurrent PPSV23. Alternative strategies are needed to prevent VZV-associated diseases in this population.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussioncontrasting

confidence: 91%

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double‐blind, placebo‐controlled trial

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Also in Japan, immunisation with live varicella vaccine (Oka/BIKEN) enhanced CMI to VZV in adults age ≥50 years [783, 784], and in subjects aged 60–70 with or without diabetes [785]. A case of recurrent HZO cured by varicella vaccination was also reported [786].…”

Section: Management and Preventionmentioning

confidence: 99%

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

et al. 2017

View full text Add to dashboard Cite

BackgroundHerpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region.MethodsWe searched PubMed, Scopus, and World Health Organization databases for articles about HZ published from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden, complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved additional HZ immunisation guidelines.ResultsFrom 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving 1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, and Thailand.HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia, secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish patients’ quality of life and incur heavy healthcare utilisation.ConclusionsSeveral countries have abundant data on HZ, but others, especially in South-East Asia, very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and HZ in particular.Electronic supplementary materialThe online version of this article (doi:10.1186/s12879-017-2198-y) contains supplementary material, which is available to authorized users.

show abstract

Assessing herpes zoster vaccine efficacy in patients with diabetes: A community‐based cohort study

Kornelius,

Lo,

Huang

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

The effectiveness of herpes zoster (HZ) vaccines in patients with diabetes over the age of 50 remains an active area of research. Utilizing a real‐world database from the US community, this study spanning from 2006 to 2023, aimed to evaluate the impact of HZ vaccination on newly diagnosed diabetes patients who received an HZ vaccination within 1 year of diagnosis. Exclusion criteria were established to omit patients with immune deficiencies. The cohort consisted of 53 885 patients, with an average age of 63.5 years, including 43% females and 58% whites. After implementing 1:1 propensity score matching for age, sex, race, comorbidities, diabetes medication, and hemoglobin A1c to ensure comparability, the study population was further stratified into four groups: N1 comparing any HZ vaccination to non‐HZ vaccination (53 882 matched pairs), N2 for Shingrix versus non‐HZ vaccination (16 665 matched pairs), N3 for Zostavax versus non‐HZ vaccination (12 058 matched pairs), and N4 for Shingrix versus Zostavax (11 721 matched pairs). Cox proportional hazards regression analysis revealed a hazard ratio (HR) for HZ incidence post any HZ vaccination of 0.92 (95% confidence interval [CI]: 0.83–1.01). Additional analyses yielded HRs of 1.12 (95% CI: 0.93–1.34) for Shingrix versus non‐HZ vaccine, 1.02 (95% CI: 0.86–1.20) for Zostavax versus non‐HZ vaccine, and 1.06 (95% CI: 0.87–1.29) for Shingrix versus Zostavax. Subgroup analyses across age, sex, and follow‐up duration also showed no significant differences. These findings underscore the lack of a significant benefit from HZ vaccination in newly diagnosed diabetes patients aged over 50, highlighting the necessity for further prospective research.

show abstract

Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus

Cited by 15 publications

References 17 publications

Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double‐blind, placebo‐controlled trial

Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double‐blind, placebo‐controlled trial

Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific

Assessing herpes zoster vaccine efficacy in patients with diabetes: A community‐based cohort study

Contact Info

Product

Resources

About